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Efficacy of Atorvastatin Reload in
Patients on Chronic Statin Therapy
Undergoing Percutaneous Coronary Intervention
Results of the ARMYDA-RECAPTURE (Atorvastatin for
Reduction of Myocardial Damage During Angioplasty) Randomized Trial
Germano Di Sciascio, MD,* Giuseppe Patti, MD,* Vincenzo Pasceri, MD,†
Achille Gaspardone, MD,‡ Giuseppe Colonna, MD,§ Antonio Montinaro, MD§
Rome and Lecce, Italy
Objectives This study was designed to investigate whether an acute atorvastatin reload before percutaneous coronary inter-
vention (PCI) protects patients receiving chronic statin therapy from periprocedural myocardial damage.
Background Previous ARMYDA (Atorvastatin for Reduction of Myocardial Damage During Angioplasty) studies demonstrated
that short-term pre-treatment with atorvastatin reduces myocardial infarction during PCI in statin-naïve patients
with both stable angina and acute coronary syndromes.
Methods A total of 383 patients (age 66  10 years, 305 men) with stable angina (53%) or non–ST-segment elevation
acute coronary syndromes (47%) and chronic statin therapy (55% atorvastatin) undergoing PCI were randomized
to atorvastatin reload (80 mg 12 h before intervention, with a further 40-mg pre-procedural dose [n  192]) or
placebo (n  191). All patients received long-term atorvastatin treatment thereafter (40 mg/day). The primary
end point was 30-day incidence of major adverse cardiac events (cardiac death, myocardial infarction, or un-
planned revascularization).
Results The primary end point occurred in 3.7% of patients treated with atorvastatin reload and in 9.4% in the placebo
arm (p  0.037); this difference was mostly driven by reduction in periprocedural myocardial infarction. There
was lower incidence of post-procedural creatine kinase-myocardial band and troponin-I elevation greater than
the upper limit of normal in the atorvastatin arm (13% vs. 24%, p  0.017, and 37% vs. 49%, p  0.021, re-
spectively). Multivariable analysis identified atorvastatin reload as a predictor of decreased risk of 30-day inci-
dence of major adverse cardiac events (odds ratio: 0.50, 95% confidence interval: 0.20 to 0.80; p  0.039),
mainly in patients with acute coronary syndromes (82% relative risk reduction; p  0.027).
Conclusions The ARMYDA-RECAPTURE trial suggests that reloading with high-dose atorvastatin improves the clinical outcome
of patients on chronic statin therapy undergoing PCI. These findings may support a strategy of routine reload
with high-dose atorvastatin early before intervention even in the background of chronic therapy. (J Am Coll Car-
diol 2009;54:558–65) © 2009 by the American College of Cardiology Foundation
ublished by Elsevier Inc. doi:10.1016/j.jacc.2009.05.028w
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tn the context of the current applications of statin therapy in
variety of clinical syndromes (1–5), the ARMYDA (Ator-
astatin for Reduction of Myocardial Damage During
ngioplasty) trial (6) demonstrated a significant reduction
f periprocedural myocardial infarction (MI) after a short-
erm pre-treatment with atorvastatin in statin-naïve patients
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ccepted May 4, 2009.ith chronic stable angina undergoing percutaneous coro-
ary intervention (PCI). This myocardial protection was
onfirmed by the ARMYDA-ACS (Atorvastatin for Re-
See page 566
uction of Myocardial Damage During Angioplasty–Acute
oronary Syndromes) trial (7), in which a pre-treatment
trategy of high-dose atorvastatin given 12 h pre-PCI in
tatin-naïve patients with acute coronary syndromes (ACS)
educed 30-day incidence of cardiac events. However, given
he large proportion of patients undergoing PCI while on
hronic statin therapy, it is unclear whether an acute statin
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imilar cardioprotective effects. Thus, the ARMYDA-
ECAPTURE trial was designed to test the hypothesis
hether an acute atorvastatin treatment on top of chronic
tatin use would translate into improved clinical outcome in
atients undergoing PCI.
ethods
tudy population and design. The ARMYDA-RECAPTURE
rial is a multicenter, randomized, prospective, double-
lind clinical trial performed in 4 Italian institutions
Campus Bio-Medico University of Rome, Vito Fazzi
ospital of Lecce, Sant’Eugenio Hospital of Rome, and
an Filippo Neri Hospital of Rome) (Fig. 1). By proto-
ol, only patients on chronic (30 days) statin therapy
ere enrolled. Clinical enrollment criteria were: 1) stable
ngina with inducible myocardial ischemia and indication
o coronary angiography; or 2) non–ST-segment elevation
CS requiring early invasive strategy. Exclusion criteria were:
T-segment elevation acute MI, non–ST-segment elevation
CS with high-risk features warranting emergency coronary
ngiography (2 h) (8), any increase in liver enzymes (alanine
848 Patients
with
stable angina
or NSTE-ACS
undergoing
coronary
angiography
R
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)
Atorvastatin reload: 
80 mg 
12 hrs before
angio; 
further 40 mg 
2 hrs before
N=229
Placebo 
12 hrs before
angio; further
dose 2 hrs
before
N=228
391 patients excluded for:
- 254 no chronic statin therapy
- 40   emergency angiography
- 86  ejection fraction <30%
- 11   severe renal failure 74 p
-
-
Figure 1 Study Design of the ARMYDA-RECAPTURE Trial
Flow chart shows the design of the ARMYDA-RECAPTURE (Atorvastatin for Reductio
tine kinase-myocardial band; Hs-CRP  high-sensitivity C-reactive protein; MI  my
PCI  percutaneous coronary intervention; TVR  target vessel revascularization.minotransferase and aspartate
minotransferase); left ventricular
jection fraction 30%, renal fail-
re with creatinine 3 mg/dl, or
istory of liver or muscle disease.
total of 848 patients fulfilling
he inclusion criteria were initially
valuated; 391 patients (46%) met
he exclusion criteria: 254 patients
30%) were excluded because they
ere not on statin therapy, 40
atients were excluded for non–
T-segment elevation ACS re-
uiring emergency intervention,
6 because of severe left ventricular
ysfunction, and 11 because of chronic renal failure. Patients’
nrollment was irrespective of type and doses of chronic statin
herapy. Eligible patients (n  457) were randomized to
eceive placebo or atorvastatin (80-mg loading given a mean of
2 h before coronary angiography, with a further 40-mg dose
pproximately 2 h before the procedure). Patients were as-
igned to the study arm using an electronic spreadsheet
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Acute Atorvastatin Reload Pre-PCI August 4, 2009:558–65ndicating the group assignment by random numbers; random-
zation blocks were created and distributed to the 4 centers.
fter coronary angiography, 74 patients (37 in each random-
zation arm) who did not receive angioplasty were excluded
rom the study (32 were treated medically and 42 with bypass
urgery); thus, 383 patients (192 randomized to atorvastatin
nd 191 to placebo) undergoing PCI immediately after diag-
ostic angiography were enrolled and represent the study
opulation. Physicians performing the procedure and the
ollow-up assessment were not aware of the randomization
ssignment.
All interventions were performed with standard tech-
ique, as previously described (6,7). According to protocol,
atients were pre-treated with aspirin (100 mg/day) and
lopidogrel (600-mg loading dose at least 3 h before the
rocedure) (9). Procedural success was defined as reduction
f stenosis to less than 30% residual narrowing. Following
CI, aspirin (100 mg/day) was continued indefinitely,
hereas clopidogrel (75 mg/day) was administered for at
east 1 month (12 months in patients treated for ACS or
eceiving drug-eluting stents). All patients after intervention
ere treated with atorvastatin (40 mg/day), irrespective of
he initial randomization assignment.
Blood samples were collected in the study patients before
nd at 8 and 24 h after PCI to measure creatine kinase-
yocardial band (CK-MB) (mass), troponin-I (mass), and
yoglobin levels; further measurements were performed in
ase of post-procedural symptoms suggestive of myocardial
schemia. Levels of CK-MB, troponin-I, and myoglobin
ere detected using the Access 2 Immunochemiluminomet-
ic assay (Beckman Coulter, Fullerton, California) (10). The
pper limit of normal (ULN) was defined as the 99th
ercentile of normal population with a total imprecision of
10%, according to Joint European Society of Cardiology/
merican College of Cardiology guidelines (11). Normal
imits were 3.6 ng/ml for CK-MB and 0.08 ng/ml for
roponin-I. C-reactive protein (CRP) levels were also mea-
ured before PCI and at 8 and 24 h after intervention.
-reactive protein was assayed by the KRIPTOR-
ltrasensitive immunofluorescent assay (BRAHMS, Hen-
igsdorf/Berlin, Germany), with detection limit of 0.06
g/l. One-month clinical follow-up was performed by
ffice visit in all study patients. Each patient gave informed
onsent to the study. The study was approved by the
nstitutional review boards of the institutions involved. The
rial was not supported by any external source of funding.
nd points. The primary end point of the ARMYDA-
ECAPTURE trial was 30-day incidence of major adverse
ardiac events (MACE): cardiac death, MI, target vessel
evascularization. Myocardial infarction was defined follow-
ng the consensus statement of the Joint European Society
f Cardiology/American College of Cardiology Founda-
ion/American Heart Association/World Heart Federation
ask Force for the Redefinition of Myocardial Infarction (or clinical trials on coronary intervention (12), as post-
rocedural increases of cardiac biomarkers (troponin or
K-MB) greater than 3 times the 99th percentile of ULN
n patients with normal baseline levels, and as a subsequent
levation 3 times in CK-MB or troponin in patients with
aised baseline levels. Target vessel revascularization in-
luded bypass surgery or repeat PCI of the target vessel(s).
Secondary end points of the study were: 1) any post-
rocedural increase of markers of myocardial injury above
LN (CK-MB and troponin-I); 2) post-procedural varia-
ions from baseline of CRP levels in the 2 arms; and 3)
ACE incidence in pre-specified clinical subgroups (stable
ngina vs. ACS), which is consistent with the earlier
RMYDA and ARMYDA-ACS trials (6,7).
tatistical analysis. In the ARMYDA and ARMYDA-
CS trials (6,7), an overall incidence of MACE at 30 days
f 18% and 17%, respectively, was observed in the placebo
rms of statin-naïve patients, which decreased by 70% with
torvastatin pre-treatment; if we hypothesize a 12% inci-
ence of events in patients on chronic statin treatment and
similar 70% reduction in patients with atorvastatin reload,
total sample size of 306 patients (153 in each group) would
rovide 80% power to detect difference with an alpha level
f 0.05.
Continuous variables between groups were compared by t
est for normally distributed values; otherwise the Mann-
hitney U test was used. Proportions were compared by
isher exact test when the expected frequency was 5,
therwise the chi-square test (Yates’ corrected) was applied.
dds ratios (ORs) and 95% confidence intervals (CIs)
ssessing the risk of the primary end point in the overall
opulation according to potential confounding variables
ere assessed by logistic regression. The following param-
ters were evaluated first in a univariate model: age, sex,
enter of enrollment, type of chronic statin therapy, use of
eta-blockers, angiotensin-converting enzyme inhibitors,
lycoprotein IIb/IIIa inhibitors, diabetes, dyslipidemia, sys-
emic hypertension, cigarette smoking, left ventricular ejec-
ion fraction, type of lesion (A/B1 vs. B2/C), multivessel
ntervention, stent length, stent diameter, use of direct
tenting, duration of balloon inflations, and use of high-
ressure post-dilation. Of these, variables with a p value
0.15 were then entered into a multivariable logistic
egression analysis. Although this may lead to an overfitted
ultivariable model, all of these variables were entered in
rder not to miss potential confounders. Multivariable
ogistic regression model was also used to evaluate the
omparison of atorvastatin reload versus placebo with regard
o incidence of MACE in pre-specified subsets, defined by
linical pattern on admission (stable angina vs. ACS).
esults are expressed as mean  SD, unless otherwise
pecified. All calculations were performed by SPSS version
2.0 (SPSS, Inc., Chicago, Illinois), and p values 0.05
2-tailed) were considered significant.
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tudy population. Clinical and procedural features in the
reatment and placebo arms are reported in Table 1 and
able 2, respectively. The 2 groups were similar for age,
ender, prevalence of diabetes mellitus (37% and 35%),
linical presentation, left ventricular function, type of
hronic statin therapy, renal function, and medical therapy
t the time of PCI. Angiographic and procedural charac-
eristics were also similar. Mean duration of chronic statin
herapy was 9.1 8.6 months in the atorvastatin reload and
.2  9.2 months in the placebo arm.
Procedural success was obtained in 191 of 192 patients
99.5%) in the treatment arm and in 190 of 191 (99.5%) in
he placebo arm. Both procedural failures were due to
nability to cross a chronic total occlusion. No patient had
2-mm side branch closure during intervention. All pa-
ients received the study-assigned drug (atorvastatin load or
lacebo) before PCI; no patient had an increase of liver
nzymes (alanine aminotransferase and aspartate amino-
ransferase) above normal limits after statin treatment.
rimary end point. The 30-day composite primary end
oint of cardiac death, MI, and target vessel revasculariza-
ion (Table 3) was observed in 3.7% of patients (7 of 192) in
he atorvastatin reload and in 9.4% (18 of 191) in the placebo
rm (p  0.037). Incidence of MACE at 1 month was
Main Demographic/Clinical Features in the AtoTable 1 Main Demographic/Clinical Feature
Variable
Male sex
Age, yrs
Diabetes mellitus
Systemic hypertension
Hypercholesterolemia
Current smokers
Previous myocardial infarction
Previous coronary intervention
Previous bypass surgery
Left ventricular ejection fraction, %
Serum creatinine, mg/dl
LDL cholesterol, mg/dl
Non–ST-segment elevation acute coronary syndrome
Multivessel coronary artery disease
Duration of statin therapy, months
Type of chronic statin therapy
Atorvastatin
Simvastatin (/ ezetimibe)
Rosuvastatin
Pravastatin
Other medical therapy
Aspirin
Clopidogrel
Beta-blockers
ACE inhibitors or ARBs
Values are given as n (%) or mean  SD.
ACE  angiotensin-converting enzyme; ARB  angiotensin receptorssentially due to periprocedural MI: 7 of 192 (3.7%) versus 17 mf 191 (8.9%). Myocardial infarction was adjudicated on the
asis of both CK-MB and troponin-I elevation (3 ULN) in
5 patients (62%), only troponin-I elevation without CK-MB
n 6 patients (25%) and only CK-MB in 3 patients (13%). One
atient in the placebo arm with severe left ventricular dysfunc-
ion (ejection fraction 30%) had PCI of the left anterior
escending artery with periprocedural MI and died suddenly 4
ays after intervention; acute stent thrombosis (by Academic
esearch Consortium definition) (13) occurred at 24 h in 1
atient of the placebo group who was successfully treated with
e-PCI; this patient did not have elevation of cardiac markers
ulfilling criteria for MI.
There were no side effects ascribable to atorvastatin or
equiring discontinuation of the drug during follow-up.
econdary end points. The prevalence of patients with
re-PCI cardiac marker elevation above ULN was similar in
he atorvastatin load and placebo groups (CK-MB: 7% vs.
%, p 0.98; troponin-I: 20% vs. 17%, p 0.63). After the
rocedure, the proportion of patients with any elevation
bove ULN of CK-MB and troponin-I was significantly
ower in the atorvastatin arm (CK-MB: 13% vs. 24%, p 
.017; troponin-I: 37% vs. 49%, p  0.021).
The CRP levels were not significantly different in the
groups before (median: 2 mg/l, interquartile range
IQR] 1 to 8 vs. 2 mg/l, IQR 1 to 5) and after PCI (5
tin Reload and Placebo Groupsthe Atorvastatin Reload and Placebo Groups
Atorvastatin
(n  192)
Placebo
(n  191) p Value
145 (76) 160 (84) 0.06
66 10 66 11 0.98
70 (37) 67 (35) 0.86
148 (77) 160 (84) 0.13
160 (83) 160 (84) 0.98
38 (20) 52 (27) 0.11
62 (32) 69 (36) 0.50
72 (38) 75 (39) 0.80
16 (8) 18 (9) 0.85
54 7 55 8 0.20
1.02 0.31 1.06 0.30 0.18
92 16 93 17 0.55
91 (47) 88 (46) 0.88
88 (46) 98 (51) 0.33
9.1 8.6 9.2 9.2 0.91
107 (55) 104 (55) 0.88
65 (34) 62 (32) 0.86
13 (7) 16 (8) 0.69
7 (4) 9 (5) 0.79
191 (99) 191 (100) 1
192 (100) 191 (100) —
80 (42) 74 (39) 0.63
124 (65) 133 (70) 0.35
r; LDL  low-density lipoprotein.rvastas ing/l, IQR 2 to 9 vs. 5 mg/l, IQR 2 to 9); PCI-induced
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Acute Atorvastatin Reload Pre-PCI August 4, 2009:558–65ncrease of CRP levels from baseline tended to be lower
n the atorvastatin reload arm (median: 1 mg/l, IQR 0 to
vs. 2 mg/l, IQR 0 to 5; p  0.10).
Patients with ACS had a significant benefit with atorva-
tatin reload (MACE incidence: 3.3% vs. 14.8% in the
lacebo arm; p  0.015), whereas event rates in patients
ith stable angina were 4% versus 4.9%, respectively (p 
.98) (Fig. 2). Test of interaction (14) between clinical
yndrome and atorvastatin reload was significant (z  2.0;
 0.022).
ultivariable analysis. Multivariable analysis (Fig. 3)
dentified atorvastatin reload as a predictor of decreased risk
f MACE at 30 days (OR: 0.50, 95% CI: 0.20 to 0.80; 50%
elative risk reduction [RRR]; p 0.039); patients receiving
Procedural Features in the Atorvastatin ReloadTable 2 Procedural Features in the Atorvast
Variable
A
Vessels treated
Left main
Left anterior descending
Left circumflex
Right coronary artery
Saphenous vein grafts
Restenotic lesions
Lesion type B2/C
Multivessel intervention
Type of intervention
Balloon only
Stent
Bifurcations with kissing balloon
No. of stents per patient
Stent diameter, mm
Total stent length, mm 1
Use of drug-eluting stents
Direct stenting
Stent deployment pressure, atm
Duration of stent deployment, s
Use of post-dilation
Use of glycoprotein IIb/IIIa inhibitors
Antithrombin therapy during intervention
Unfractionated heparin
Bivalirudin
Values are given as n (%) or mean  SD.
ndividual and Combined Outcome Measures of therimary End Point at 30 Days in the Atorva tatinelo nd Placebo Groups
Table 3
Individual and Combined Outcome Measures of the
Primary End Point at 30 Days in the Atorvastatin
Reload and Placebo Groups
Atorvastatin Reload
(n  192)
Placebo
(n  191) p Value
Cardiac death 0 1 (0.5) NS
Myocardial infarction 7 (3.7) 17 (8.9) 0.056
Stent thrombosis 0 1 (0.5) NS
Target vessel revascularization 0 1 (0.5) NS
Total MACE 7 (3.7) 18 (9.4) 0.037b
alues are given as n (%). The events are not mutually exclusive.
MACE  major adverse cardiac events.ultiple stent implantation had an increased risk of events,
s well as those requiring periprocedural use of glycoprotein
Ib/IIIa inhibitors. No difference in benefit was found with
eload in patients treated with drug-eluting versus bare-
etal stents or bivalirudin versus unfractionated heparin.
ogistic regression analysis in the pre-specified clinical
ubgroups revealed a significant benefit on 30-day MACE
n response to atorvastatin reload in patients with ACS
OR: 0.18, 95% CI: 0.10 to 0.83; RRR: 82%; p  0.027)
nd a nonsignificant benefit in those with stable angina
OR: 0.74, 95% CI: 0.20 to 2.9; p  0.70).
iscussion
he ARMYDA-RECAPTURE trial indicates that a short-
erm pre-treatment with high-dose atorvastatin load before
CI improves outcome in patients already receiving chronic
tatin therapy. In particular, an acute bolus of 80-mg
torvastatin given 12 h before intervention followed by a
urther 40-mg pre-procedural dose was associated with 50%
elative risk reduction of MACE at 30 days versus placebo.
s such, given the large proportion of patients (70% in the
RMYDA-RECAPTURE centers) undergoing PCI while
n chronic statin therapy, the study answers a relevant
uestion in interventional cardiology. Excluding 1 cardiac
eath in the placebo arm, the benefit was essentially driven
lacebo GroupsReload and Placebo Groups
tatin
92)
Placebo
(n  191) p Value
228 —
) 2 (1) 0.63
2) 103 (45) 0.62
9) 56 (24) 0.33
7) 61 (27) 0.98
) 6 (3) 0.69
) 19 (10) 0.99
6) 101 (53) 0.58
8) 34 (18) 0.91
) 11 (6) 0.84
3) 180 (94) 0.84
) 5 (3) 0.76
0.7 1.3 0.7 0.99
0.6 2.9 0.5 0.96
7.2 17.1 7.7 0.69
2) 69 (36) 0.57
1) 74 (39) 0.71
3.9 13 3.6 0.96
9 18 8 0.94
8) 75 (39) 0.88
2) 23 (12) 0.89
0) 170 (89) 0.85
0) 21 (11) 0.85and Patin
torvas
(n  1
231
2 (1
98 (4
67 (2
61 (2
3 (1
18 (9
108 (5
34 (1
13 (7
179 (9
5 (3
1.3
2.9
6.8
63 (3
79 (4
13
18
73 (3
23 (1
173 (9
19 (1y a 2.4-fold reduction of periprocedural MI; myocardial
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August 4, 2009:558–65 Acute Atorvastatin Reload Pre-PCIrotection by atorvastatin reload was also expressed by
ignificantly lower proportion of patients with post-
rocedural increase of cardiac markers (CK-MB and tropo-
in-I); according to our data, 17 patients should be reloaded
ith atorvastatin in order to prevent 1 adverse event
number needed to treat).
In the original ARMYDA (6) and in the ARMYDA-
CS (7) trials only statin-naïve patients were enrolled. In
he former study, patients with chronic stable angina were
andomized to receive 7-day pre-treatment before PCI with
torvastatin 40 mg/day or placebo, and a significant 81%
isk reduction of periprocedural MI was observed in the
tatin arm. The ARMYDA-ACS trial more recently en-
olled patients with unstable angina or non–ST-segment
levation ACS, in whom a scheme of atorvastatin administra-
ion similar to the ARMYDA-RECAPTURE trial led to 88%
isk reduction of cardiac events at 1 month versus placebo, as
ell as to a 3-fold reduction of periprocedural MI.
Possible mechanisms of atorvastatin cardioprotection
ave been investigated in the ARMYDA-CAMs (Atorva-
tatin for Reduction of Myocardial Damage During Angio-
lasty–Cell Adhesion Molecules) study (15), a planned
ubanalysis demonstrating that procedural protection in the
Atorvasta
%
4
4.9
P=0.98
0
3
6
9
12
15
Stable angina
Figure 2 Secondary End Points
Incidence of major adverse cardiac events at 30 days according to clinical present
Figure 3 Odds Ratio for 30-Day Major Adverse Cardiac Events
Results of multivariable analysis showing 50% major adverse cardiac events risk r
30 days with atorvastatin (p  0.039). Log axis has been used to present the oddtorvastatin arm was paralleled by reduction of PCI-induced
ndothelial activation, as expressed by significant attenua-
ion in the increase of intercellular cell adhesion molecule-1
nd E-selectin levels at 24 h after intervention. Other
xplanations include atorvastatin-induced early increase of
ndothelial progenitors cells differentiation and subsequent
ugmentation of circulating endothelial progenitors cells,
ith attendant cardioprotective effects (16). Those acute
ffects of short-term treatment may support a lipid-lowering
ndependent mechanism of action; this is in accordance also
ith animal studies that have shown a reduction of infarct
ize when an acute statin load is given before ischemia (17)
r before reperfusion (18). Interestingly, whereas in the
nimal model this cardioprotection may wane with time, it
an be restored with an acute high dose atorvastatin given
mmediately before ischemia/reperfusion (19,20); this phe-
omenon may have potential clinical relevance.
Thus, the primary benefit derived from atorvastatin
eload in the ARMYDA-RECAPTURE trial appears to be
gain a reduction in periprocedural MI, largely localized to
hose patients who presented with ACS. Indeed, the relative
agnitude of benefit afforded patients with ACS (MACE
RR of 82%; p  0.027), compared with stable angina
Placebo
%
3.3
14.8
P=0.015
0
3
6
9
12
15
18
ACS
(stable angina vs. acute coronary syndrome). ACS  acute coronary syndrome.
on at
s. LVEF  left ventricular ejection fraction.tin
ationeducti
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Acute Atorvastatin Reload Pre-PCI August 4, 2009:558–65atients (MACE reduction of 26%; p  0.70) is striking and
rives the benefit observed for oral atorvastatin loading. Anal-
sis of interaction between acuity of clinical presentation and
esponse to atorvastatin reload was significant in favor of ACS
atients. It would appear then that statin-naïve patients un-
ergoing either elective PCI for chronic stable angina or
emi-urgent PCI for ACS enjoy a significant reduction in
ACE following oral atorvastatin loading regimens (21–23),
s confirmed also by the recent NAPLES II (Novel Ap-
roaches for Preventing or Limiting Events II) trial (24),
hich used a single 80-mg atorvastatin bolus before PCI.
owever, among chronic statin-treated patients, those pre-
enting with ACS derive disproportionate benefit and, accord-
ng to our study, should receive atorvastatin reload. This
ppropriate, selective reloading of the ACS cohort is illustrated
y a number needed to treat of 9 in order to prevent 1 MACE
ersus 111 for patients with stable angina. Although the
athophysiological explanation for atorvastatin loading benefit
n statin-naïve patients could be lack of statin-mediated plaque
tabilizing effect (25,26), in ACS patients “breakthrough”
laque instability with increased or “resistant” plaque inflam-
ation likely explains the relative benefit of atorvastatin reload.
he rapid, anti-inflammatory, antithrombotic effects of ator-
astatin have been described (27,28).
It is likely that ACS patients have increased plaque
nflammatory cell density (macrophages and T lymphocytes)
ith consequent greater local production of inflammatory
ytokines (15), as well as suppression of anti-inflammatory
ediators (nitric oxide synthase). Thus, although it is
onceivable that patients on chronic statin therapy would
lready have some degree of myocardial protection during
CI, the presence of breakthrough plaque inflammation in
he ACS cohort requires the acute suppression afforded by
torvastatin reload (similar to the observation made in the
riginal ARMYDA-ACS study) (7). Furthermore, a dose-
ependent platelet inhibitory/anti-inflammatory effect of
torvastatin may have been operative: in vivo platelet acti-
ation and plasma chemokine levels have been demon-
trated to be reduced more effectively by higher atorvastatin
oses through low-density lipoprotein-independent mech-
nisms (29). As thrombosis and inflammation are intrinsi-
ally linked in the pathogenesis of periprocedural myone-
rosis in the setting of PCI, especially in ACS patients, this
oncept may support the utilization of high dose, intensive
torvastatin load in our study.
If these observations regarding an independent, selective
enefit of statin reloading in ACS patients are confirmed by
uture studies, the ARMYDA-RECAPTURE trial may
ave significant influence in clinical practice for the acute
are of non–ST-segment elevation ACS.
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APPENDIX
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lease see the online version of this article.
